Hubert van Hoogstraten
Genzyme
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hubert van Hoogstraten.
Arthritis & Rheumatism | 2015
Mark C. Genovese; R. Fleischmann; Alan Kivitz; Maria Rell-Bakalarska; Renata Martincova; Stefano Fiore; Patricia Rohane; Hubert van Hoogstraten; Anju Garg; Chunpeng Fan; Janet van Adelsberg; Steven P. Weinstein; Neil Stahl; George D. Yancopoulos; Tom W J Huizinga; Désirée van der Heijde
To evaluate the efficacy and safety of sarilumab in combination with methotrexate (MTX) for the treatment of rheumatoid arthritis (RA).
Annals of the Rheumatic Diseases | 2017
Gerd R. Burmester; Yong Lin; Rahul Patel; Janet van Adelsberg; E.K. Mangan; Hubert van Hoogstraten; Deborah Bauer; Juan Ignacio Vargas; Eun Bong Lee
Objectives To compare efficacy and safety of sarilumab monotherapy with adalimumab monotherapy in patients with active rheumatoid arthritis (RA) who should not continue treatment with methotrexate (MTX) due to intolerance or inadequate response. Methods MONARCH was a randomised, active-controlled, double-blind, double-dummy, phase III superiority trial. Patients received sarilumab (200 mg every 2 weeks (q2w)) or adalimumab (40 mg q2w) monotherapy for 24 weeks. The primary end point was change from baseline in 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) at week 24. Results Sarilumab was superior to adalimumab in the primary end point of change from baseline in DAS28-ESR (−3.28 vs −2.20; p<0.0001). Sarilumab-treated patients achieved significantly higher American College of Rheumatology 20/50/70 response rates (sarilumab: 71.7%/45.7%/23.4%; adalimumab: 58.4%/29.7%/11.9%; all p≤0.0074) and had significantly greater improvement in Health Assessment Questionnaire-Disability Index (p=0.0037). Importantly, at week 24, more patients receiving sarilumab compared with adalimumab achieved Clinical Disease Activity Index remission (7.1% vs 2.7%; nominal p=0.0468) and low disease activity (41.8% vs 24.9%; nominal p=0.0005, supplemental analysis). Adverse events occurred in 63.6% (adalimumab) and 64.1% (sarilumab) of patients, the most common being neutropenia and injection site reactions (sarilumab) and headache and worsening RA (adalimumab). Incidences of infections (sarilumab: 28.8%; adalimumab: 27.7%) and serious infections (1.1%, both groups) were similar, despite neutropenia differences. Conclusions Sarilumab monotherapy demonstrated superiority to adalimumab monotherapy by improving the signs and symptoms and physical functions in patients with RA who were unable to continue MTX treatment. The safety profiles of both therapies were consistent with anticipated class effects. Trial registration number NCT02332590.
Arthritis & Rheumatism | 2017
Roy Fleischmann; Janet van Adelsberg; Yong Lin; Geraldo da Rocha Castelar-Pinheiro; Jan Brzezicki; Paweł Hrycaj; Hubert van Hoogstraten; Deborah Bauer; Gerd R. Burmester
To evaluate the efficacy and safety of sarilumab plus conventional synthetic disease‐modifying antirheumatic drugs (DMARDs) in patients with active moderate‐to‐severe rheumatoid arthritis (RA) who had an inadequate response or intolerance to anti–tumor necrosis factor (anti‐TNF) therapy.
Arthritis & Rheumatism | 2016
Roy Fleischmann; Janet van Adelsberg; Yong Lin; Geraldo da Rocha Castelar-Pinheiro; Jan Brzezicki; Paweł Hrycaj; Hubert van Hoogstraten; Deborah Bauer; Gerd R. Burmester
To evaluate the efficacy and safety of sarilumab plus conventional synthetic disease‐modifying antirheumatic drugs (DMARDs) in patients with active moderate‐to‐severe rheumatoid arthritis (RA) who had an inadequate response or intolerance to anti–tumor necrosis factor (anti‐TNF) therapy.
Arthritis Research & Therapy | 2016
Vibeke Strand; Mark Kosinski; Chieh-I Chen; George J. Joseph; Regina Rendas-Baum; Hubert van Hoogstraten; Martha S. Bayliss; Chunpeng Fan; Tom W J Huizinga; Mark C. Genovese
RMD Open | 2017
Vibeke Strand; Matthew Reaney; Chieh-I Chen; C Proudfoot; Sophie Guillonneau; Deborah Bauer; E.K. Mangan; Hubert van Hoogstraten; Yong Lin; César Pacheco-Tena; Roy Fleischmann
Rheumatology and Therapy | 2018
Alan Kivitz; Lydie Baret-Cormel; Hubert van Hoogstraten; Sheldon Wang; Janie Parrino; Christine Xu; Marina Stanislav
Rheumatology | 2018
Paul Emery; Hubert van Hoogstraten; S Jayawardena; E.K. Mangan; Paula Cejas; Patrick Verschueren
Rheumatology | 2018
Roy Fleischmann; Hubert van Hoogstraten; S Jayawardena; E.K. Mangan; Daniel Ching; Gerd R. Burmester
Rheumatology | 2018
Mark C. Genovese; E.K. Mangan; J. Fay; Toshio Kimura; Hubert van Hoogstraten; Roy Fleischmann